HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Mark D Leibowitz Selected Research

LG 268

2/2006Biological characterization of a heterodimer-selective retinoid X receptor modulator: potential benefits for the treatment of type 2 diabetes.
2/2004Activation of the retinoid X receptor suppresses appetite in the rat.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Mark D Leibowitz Research Topics

Disease

2Insulin Resistance
02/2006 - 05/2004
2Body Weight (Weight, Body)
02/2006 - 02/2004
1Inflammation (Inflammations)
05/2008
1Type 2 Diabetes Mellitus (MODY)
02/2006
1Hypertriglyceridemia
02/2006
1Weight Gain
02/2006
1Hypothyroidism
08/2002
1Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous)
08/2002

Drug/Important Bio-Agent (IBA)

3LG 100268IBA
02/2006 - 08/2002
3Insulin (Novolin)FDA Link
02/2006 - 02/2004
2LG 268IBA
02/2006 - 02/2004
2Retinoid X Receptors (Retinoid X Receptor)IBA
02/2006 - 08/2002
1GlucocorticoidsIBA
05/2008
12,4-thiazolidinedione (thiazolidinedione)IBA
02/2006
17- (2- (2,2- difluoroethoxy)- 3,5- di- tert- butylbenzene)- 3- methylocta- 2,4,6- trienoic acidIBA
02/2006
1Rosiglitazone (Avandia)FDA Link
02/2006
1Biological ProductsIBA
02/2006
1Triglycerides (Triacylglycerol)IBA
02/2006
1PPAR gammaIBA
02/2006
1Thyroid HormonesIBA
02/2006
1Hormones (Hormone)IBA
08/2002
1Bexarotene (LGD1069)FDA Link
08/2002

Therapy/Procedure

1Therapeutics
02/2006